Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CP-675, 206 · 8 trials · 10 indications
| Arm | Type | Description |
|---|---|---|
| B | ACTIVE_COMPARATOR | Choice of one or the other Dacarbazine or Temozolomide(CP-675,206) (choice) |
| A | EXPERIMENTAL | - |
| 1 | EXPERIMENTAL | Drug: CP-675,206 (Tremelimumab) |
| Arm A | EXPERIMENTAL | - |
| Arm B | ACTIVE_COMPARATOR | - |
| 15 mg/kg CP-675,206 | EXPERIMENTAL | - |
| 10 mg/kg | EXPERIMENTAL | pts treated at 10 mg/kg dose level on a monthly regimen |
| 15 mg/kg | EXPERIMENTAL | pts treated at 15 mg/kg dose level on a quarterly regimen |
| Commercial Formulation | EXPERIMENTAL | Commercial Formulation |
| Current Formulation | EXPERIMENTAL | Current Formulation |
| Name | Type | Description |
|---|---|---|
| dacarbazine | DRUG | decarbazine 1000 mg/m2 IV Q 21 days x 12 |
| CP-675,206 | DRUG | CP-675,206 15 mg/kg IV Q 90 days x 4 |
| temozolomide | DRUG | temozolomide 200 mg/m2 orally on Days 1-5 every 28 days x 12 |
| CP-675,206 (Tremelimumab) | DRUG | 15 mg/kg IV every 3 months as long as required |
| best supportive care | DRUG | As per investigator discretion. Excludes chemotherapy or other anti-cancer therapy |
| SU011248 | DRUG | SU011248 administered at a dose of 37.5mg/day every day. |
Inclusion Criteria: * Surgically incurable melanoma, either Stage IV or IIIC with N3 status for regional lymph nodes and in-transit or satellite lesions. * Serum lactic acid dehydrogenase (LDH) \<= 2 x ULN * ECOG performance status of 0 or 1 Exclusion Criteria: * Received any systemic therapy for...
Top 20 of 51 competitors
CP-675,206 is an investigational oncology therapy being studied in prostatic neoplasms, melanoma, pancreatic cancer, renal cell carcinoma, non-small-cell lung cancer, and colorectal neoplasms. It is a small molecule being developed by AstraZeneca PLC and is currently in Phase 2 clinical development.
CP-675,206 is a small molecule oncology therapy. Its specific molecular target has not been disclosed in available clinical trial information. The drug is being investigated across multiple solid tumor types including melanoma, renal cell carcinoma, and non-small-cell lung cancer.
CP-675,206 is being developed by AstraZeneca PLC, a biopharmaceutical company listed on the stock exchange under the ticker AZN. The drug is currently in Phase 2 clinical trials for multiple oncology indications.
CP-675,206 is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. Two Phase 2 trials have been completed, along with two Phase 1 trials, with a total enrollment of 740 patients across all studies.
CP-675,206 has completed two Phase 2 trials: NCT00086489 in advanced melanoma and NCT00312975 in non-small-cell lung cancer. Two Phase 1 trials, NCT00372853 in metastatic renal cell carcinoma and NCT00431275 in melanoma, have also been completed. All trials are closed.
CP-675,206 is an investigational monoclonal antibody being developed by AstraZeneca. While it has been studied in oncology indications, no alternative names have been established in the clinical trial records. The drug remains in Phase 2 development.